SCHEMBL6366000

SCHEMBL6366000

CCC(CC)(CCn1ccn(CC(=O)c2cc(N3CCCC3)c(OCCCCC(=O)O)c(C(C)(C)C)c2)c1=N)OC

nearest known ligand 0.38

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
F2R P25116 17/20 0.38
RARA P10276 3/20 0.33
RARB P10826 3/20 0.33
RARG P13631 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL4333522 0.99 F2R (0.38) F2RRARARARBRARG
SCHEMBL6362187 0.83 F2R (0.36) F2RRARARARBRARG
Bromide SCHEMBL4337575 0.83 F2R (0.36) F2RRARARARBRARG
SCHEMBL14346311 0.77 F2R (0.47) F2R
Bromide SCHEMBL4344870 0.76 F2R (0.46) F2R
SCHEMBL4337976 0.75 F2R (0.35) F2R
Bromide SCHEMBL5585079 0.75 F2R (0.35) F2R
SCHEMBL6362075 0.73 F2R (0.38) F2RRARARARBRARG
Bromide SCHEMBL4338146 0.73 F2R (0.38) F2RRARARARBRARG
Trifluoroacetic Acid SCHEMBL6750474 0.71 F2R (0.53) F2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7304083-B2 2-iminoimidazole derivatives (2) EISAI R&D MANAGEMENT CO., LTD. (JP) 2007-12-04 US disclosed
US-7304083-B2 2-iminoimidazole derivatives (2) EISAI R&D MANAGEMENT CO., LTD. (JP) 2007-12-04 US disclosed
US-20050004197-A1 2-iminoimidazole derivatives (2) EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004197-A1 2-iminoimidazole derivatives (2) H1-2, H1-3, H1-4 F2R 2393/4885RARA 2153/4885RARB 2718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.